COVID-19 vaccine developed by China to include 50,000 people in phase 3 clinical trial

Taking China's research for COVID-19 vaccine a step furr, a Chinese pharmaceutical company has said on September 5 that around 50,000 people across several countries are participating in final phase of clinical trials of its vaccine candidate for dely disease caused by vel coronavirus. China National Biotec Group (CNBG) reportedly said in a statement carried by ANI that phase 3 clinical trials of its COVID-19 vaccine candidate is “significantly accelerating”  including countries such as UAE, Bahrain, Morocco, Peru, Argentina among ors. 

" third phase of clinical trials of inactivated CNBG vaccine against COVID-19 is significantly accelerating, and clinical trials are alrey underway in several countries, including Bahrain, UAE, Morocco, Peru, Argentina, with about 50,000 people participating," CNGB said.

Meanwhile, CNBG and Sivac Biotech Ltd have also said on September 5 that y each have found two more countries to run ir late-st clinical tests. While Serbia and Pakistan agreed to participate in CNBG’s trial, Turkey and Banglesh are w a part of Sivac vaccine trials as China continues to ramp up its efforts to get a suitable vaccine to COVID-19. According to international media reports, Serbia will test two vaccines developed by CNBG units at Wuhan and Beijing and Pakistan will only test one developed by Beijing unit. 

CNBG vice president Zhang Yuntao has also told an international media ncy that apart from participation of at least 10 countries in phase 3 clinical trials of ir vaccine candidate, several foreign countries have expressed ir interest in ordering a combined 500 million doses of its vaccines. company would be able to produce at least 300 million doses of its COVID-19 vaccine candidate every year that too only after upgring of its manufacturing techniques. 

Re - Kamala Harris: 'Can't Trust Trump' On COVID Vaccine, Health Experts Would Be 'suppressed'

Re - Moscow's COVID-19 Death Toll Soars To 4,891 As Russia Tests 'Sputnik V' Vaccine

WHO chief scientist on COVID-19 vaccine distribution

Meanwhile, World Health Organization's (WHO) chief scientist Dr Soumya Swaminathan has said on September 4 that global distribution of COVID-19 vaccine on a mass level may only be able to take place by mid-2021. This came as worldwide vel coronavirus infections are nearing 30 million with more than 4.1 million in India alone. global death toll has mounted to 880,008 as per Johns Hopkins University tally and India has recorded more than 70k deaths.  

"So realistically speaking, probably second half, middle of 2021 - maybe second quarter, third quarter of 2021 - is when we can start seeing doses actually flowing into countries so that y can start to immunize ir populations," Swaminathan said while dressing a press briefing.

Re - US Election 2020: Kamala Harris Touts Trump's Push For COVID-19 Vaccine As Re-election Bid

Re - Centre For Assessing Clinical Immugenicity For Viral Vaccines Inaugurated

(With inputs from ncies)

Im: Representative/ Unsplash